WHO prioritizing Gilead’s remdesivir, designing master protocol for 2019-nCoV outbreak
WHO plans to establish master protocol for 2019-nCoV outbreak
Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group.
The group agreed in principle to design a randomized, controlled master protocol that can compare multiple investigational therapies in parallel.
The report, circulated to the group on Jan. 29, states: “Among the different therapeutic options, Remdesivir was considered the most promising candidate based on the broad antiviral spectrum, the in vitro and in